Key Highlights – April to End of June
- New step forward for NeoImmuneTech’s partnership with U.S. National Institute of Allergy and Infectious Diseases (NIAID), for drug development in Acute Radiation Syndrome (ARS).
- Innovative investigational therapeutic approach combining pembrolizumab, GX-188E therapeutic DNA vaccine, and the T-cell amplifier NT-I7 (IL-7, GX-I7) opens a new promising development opportunity.
In the second quarter 2023, NeoImmuneTech showcased the advancements in its clinical development program at three significant events: the American Society of Clinical Oncology (ASCO) Annual Meeting, the Bio International Convention (BIO 2023), and the 4th Annual Cytokine-Based Drug Development Summit.
On June 3, at ASCO 2023, NeoImmuneTech presented a Trial In Progress poster (abstract: TPS2085, poster Bd #:439b), which outlined the design of the phase 2 study NIT-120 exploring the efficacy and safety of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma. The decision to pursue this study was based on promising preliminary findings, demonstrating improved survival in murine glioma models when NeoImmuneTech's NT-I7 was combined with pembrolizumab.
On June 6, another poster (abstract: 6075, poster Bd #:67) presented at ASCO 2023 highlighted the early results of a single arm phase 2 study. The study investigated the combined treatment of neoadjuvant pembrolizumab, GX-188E therapeutic DNA vaccine, and the T-cell amplifier NT-I7 (IL-7, GX-I7) in patients with human papillomavirus-16- and/or 18-positive. The initial findings exhibited positive outcomes with manageable safety profiles. This investigational therapeutic approach, based on the long-acting human IL-7 that both NeoImmuneTech and Genexine are developing, offers potential for further clinical considerations regarding NT-I7.
On June 7, at BIO 2023, Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech, presented an update on NIT’s clinical program. Part of this presentation were the interim results of study NIT-110, showing a median Overall Survival (mOS) of 48.3 weeks in patients with checkpoint inhibitor (CPI)-naïve Microsatellite Stable Pancreatic Cancer (PC) treated with NT-I7 and pembrolizumab.
On June 20, NIT announced the commencement of a groundbreaking study in rodent models with the National Institute of Allergy and Infectious Diseases (NIAID). This collaboration will explore the potential of NT-I7 in the treatment of Acute Radiation Syndrome (ARS). It builds on the non-clinical evaluation agreement between NeoImmuneTech, Inc. and the National Institute of Allergy and Infectious Diseases (NIAID), signed at the end of 2022.
From June 27-29, NIT made its mark at the 4th Annual Cytokine-Based Drug Development Summit, in Boston. We had the privilege of seeing three of our scientific leaders and experts take the stage - SVP & Chief Scientific Officer, Byung Ha Lee, Director of Clinical Science, Sara Ferrando-Martinez, and Senior Scientist, Alexandra Wolfarth. They delivered a series of compelling presentations on the potential of cytokines with particular focus on the promising long-acting IL-7, NT-I7.
*** ENDS ***
Media inquiries: firstname.lastname@example.org